| abstract |
The present invention relates to pharmaceutical formulations of ARN-509 which can be administered to a mammal suffering from, in particular, a human: androgen receptor (AR) related disease or condition, in particular cancer, more particularly prostate cancer, including but It is not limited to castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy-induced metastatic castration-resistant prostate cancer, biochemical relapsing hormone-sensitive prostate cancer, or high-risk non-metastatic castration-resistant prostate cancer. In one aspect, the formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS can be obtained by melt extrusion of a mixture comprising ARN-509 and HPMCAS and optionally milling the melt extruded mixture, in particular by Get it by doing this. In one aspect, a solid dispersion of ARN-509 and HPMCAS can be obtained by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent, particularly by doing so. |